Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses new treatments for HR+/HER2- breast cancer and immunotherapy challenges, ...

Revenue: Revenue was $0 for the third quarter of 2024, as compared to $25.2 million for the third quarter of 2023. The decrease was primarily due to the recognition of previously received milestone ...

Breast cancer has been a formidable health challenge ... The CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib were approved for HR-positive, HER2-negative disease, blocking cyclin ...

Kisqali (ribociclib) given alongside endocrine therapy as adjuvant therapy for patients with stage 2 or 3 hormone receptor-positive, HER2-negative breast cancer reduced patients’ risk for ...

Analyst Andrew Berens of Leerink Partners maintained a Buy rating on Relay Therapeutics (RLAY – Research Report), retaining the price ...

NEW HAVEN, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...

The Food and Drug Administration (FDA) has just approved Novartis’ Kisqali (ribociclib) in combination with an aromatase inhibitor as treatment for people with HR+/HER2- stage II and III early breast ...

A Michigan State University researcher's new model for studying breast cancer could help scientists better understand why and ...

University of Kentucky Markey Cancer Center researchers identified a protein that could be key to developing new treatments ...

Cleveland Clinic researchers are presenting updated findings from their novel study of a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease.

Disease progression in metastatic breast cancer is a challenge that no single entity can solve alone. Breakthroughs in ...

Breast cancer rates rose by 1 percent per year from 2012-2021 for all U.S. women combined, with steeper increases for women ...